Vaxart, a clinical-stage biotech company, has published a presentation urging shareholders to vote for all six of its director nominees at the upcoming Annual Meeting. The company highlights its progress in developing oral vaccines for COVID-19, norovirus, and influenza, and emphasizes its board's expertise in navigating regulatory and funding challenges, including securing BARDA funding and raising capital. Vaxart warns that replacing any current directors with dissident nominees lacking biotech experience could risk the company's momentum. Shareholders are encouraged to vote on the WHITE proxy card to support the board's strategic direction and value creation efforts.
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now accessible on-demand for 90 days. This event featured multiple life sciences companies presenting to investors, with opportunit...
Axsome Therapeutics has initiated the FOCUS-3 Phase 3 clinical trial to evaluate solriamfetol as a treatment for adolescents aged 12 to under 18 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to asse...
WuXi AppTec highlights how the increasing structural complexity of small molecules, such as targeted protein degraders and covalent inhibitors, is transforming drug research and development. These new molecules require advanced, integrated approaches...
At its Annual General Meeting on June 25, 2026, Fury Gold Mines shareholders approved fixing the board size at six directors and elected all nominated directors. PricewaterhouseCoopers LLP was appointed as the company's auditor. Shareholders also ren...
SoundHound AI's Chief Operating Officer has sold 65,000 shares of the company's stock. This insider sale could indicate personal financial decisions or a strategic move related to the company's outlook. Investors often watch such transactions closely...
